Plain-English translation of NCT06800469 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Pancreatic cancer surgery is a major operation with a high risk of serious complications after the procedure. This study is investigating whether the types of bacteria living in a patient's gut might influence how well they recover from this surgery. Researchers will analyze gut bacteria samples from patients undergoing pancreatic cancer surgery to see if certain bacterial types are associated with better or worse recovery.
Even in the best hospitals, pancreatic cancer surgery leads to complications in about 7 out of 10 patients, sometimes with life-threatening infections. Doctors know some risk factors (like age and other health conditions), but no one has studied whether gut bacteria might predict which patients will have the most problems. If researchers can identify protective or harmful bacteria, it could help doctors predict complications and develop new ways to prevent them.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will provide stool samples before and after your scheduled pancreatic cancer surgery so researchers can analyze your gut bacteria. The study will collect information about any complications you experience after surgery and compare these outcomes to your bacterial profiles. The research team will follow your recovery to see if specific bacterial types are linked to better or worse surgical outcomes.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Italy
Sponsor
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Enrollment target
~30 participants
Started
July 2022
Primary completion
July 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Claudio Ricci, MD
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.